The primary therapeutic role of Tevagrastim (Filgrastim) is to provide essential supportive care when patients experience severe neutropenia, a condition involving critically low levels of infection-fighting white blood cells. Its use is relevant across therapeutic domains where acute or disruptive symptom patterns linked to immune vulnerability are present.

---

This medicine is generally used in patients experiencing profound immune cell depletion due to intensive chemotherapy, in individuals with Severe Chronic Neutropenia (SCN), and in those undergoing stem cell transplantation to facilitate cell collection and recovery. The medicine may assist in addressing groups of symptoms that may become intense or disruptive, helping to minimize the onset of serious manifestations like febrile neutropenia (fever associated with low counts). The use of Tevagrastim supports patients during difficult symptomatic episodes.

“The administration of this medicine supports the patient during phases of heightened symptoms by easing distress and contributing to improved day-to-day comfort.”

Quick Fact: Relief for Systemic Strain and Symptom Fluctuation

Tevagrastim is applied in clinical settings that involve acute or unstable symptom patterns, which are conditions presenting with systemic or localized discomfort. Its use supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

1. European Medicines Agency Product Information for Tevagrastim

Who Can and Cannot Use Tevagrastim?

The population eligibility for Tevagrastim (Filgrastim) is strictly defined by regulatory authorities based on contraindications, existing medical conditions, and patient demographics.

Contraindications and Non-Eligibility

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Individuals with known hypersensitivity or severe allergic reactions to the active substance Filgrastim or any of the excipients [Source: EMA/FDA].
Populations for whom use is not recommended	Use is not recommended within the 24 hours before or the 24 hours after administration of cytotoxic chemotherapy or radiotherapy.
Eligibility-related restrictions	Use is not established/indicated in patients with Chronic Myeloid Leukemia (CML) or Myelodysplastic Syndromes (MDS).

Age, Organ Function, and Reproductive Status

Category	Official Regulatory Statement
Age-related eligibility rules	Pediatric (Children): Safety and efficacy are similar to adults receiving chemotherapy. Geriatric (Older Adults): Specific dosage recommendations cannot be made due to limited patient data in trials.
Condition-specific eligibility rules	Renal or Hepatic Impairment: Dose adjustment is not required for patients with severe impairment of kidney or liver function.
Pregnancy and lactation eligibility status	Pregnancy: Use is conditional and permitted only if the potential benefit justifies the potential risk to the fetus. Lactation: Breastfeeding is not recommended.

Interactions with Other Medicines and Products

The interaction profile of Tevagrastim (Filgrastim) is primarily defined by regulatory requirements concerning its use alongside cytotoxic treatments and its potential additive effects with certain other medicines.

Mandatory Administration Timing Separation

Interacting Product Category	Official Restriction/Requirement
Cytotoxic Chemotherapy	Must not be administered within the period starting 24 hours before and ending 24 hours after the administration of cytotoxic agents.
Radiotherapy	Must not be administered within the period starting 24 hours before and ending 24 hours after radiotherapy sessions.

This mandatory separation ensures that the rapidly proliferating progenitor cells stimulated by Tevagrastim are not damaged by the cytotoxic treatments.

Pharmacodynamic Caution

Agents that may potentiate the release of neutrophils, such as lithium, should be used with caution alongside Tevagrastim. This caution is noted in regulatory information due to the potential for an additive effect on neutrophil counts.

Absence of Pharmacokinetic Data

Formal drug interaction studies between filgrastim products and other medicines have not been performed. Consequently, there is no official documentation in the regulatory prescribing information concerning interactions that alter Tevagrastim's exposure or clearance through metabolic pathways (e.g., CYP enzymes) or drug transporters.

Tevagrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that acts upon specific hematopoietic pathways to influence neutrophil lineage development.

G-CSF Receptor Agonism and Intracellular Signaling

Tevagrastim engages the G-CSF receptor (CD114) on bone marrow progenitor cells, acting as an agonist. This binding initiates the JAK/STAT signaling cascade, an early molecular step that drives cellular progression via transcription and translation of proliferation and differentiation instructions.

Enhanced Myeloid Cell Production

Activation of the signaling cascade upregulates genes responsible for promoting cell division and accelerated maturation within the neutrophil lineage (myeloid cells). This mechanism influences intracellular signaling that promotes cell division, resulting in an increase in the number of circulating neutrophils.

Mobilization of Progenitor Cells

Beyond bone marrow effects, Tevagrastim also influences cellular adhesion mechanisms. It facilitates the release of hematopoietic stem and progenitor cells (HSPCs) from the bone marrow into the peripheral blood by engaging mechanisms that regulate the chemokine CXCL12 and its receptor CXCR4. This action facilitates the presence of hematopoietic progenitor cells in the peripheral blood circulation.

Administration Guidelines for Tevagrastim (Filgrastim)

Authorized protocols detail specific rules for the proper administration and dosing of Tevagrastim, which is a solution for injection or infusion, ensuring its use follows defined requirements.

Field	Official Administration Guideline
Route of Administration	Tevagrastim is administered by subcutaneous (SC) injection (preferred route) or intravenous (IV) infusion.
Dosing Schedule	Dosing is typically weight-based, commonly starting at 5 mu g/kg/day for chemotherapy-induced neutropenia. Doses for severe chronic neutropenia and peripheral blood progenitor cell (PBPC) mobilization are higher, such as 10 mu g/kg/day or 12 mu g/kg/day.
Frequency and Timing	Administration is daily until the neutrophil count recovers or is stabilized. A critical rule mandates the first dose must be given no earlier than 24 hours after the completion of cytotoxic chemotherapy and not within 24 hours prior to chemotherapy.
Preparation Requirements	For a more comfortable SC injection, the pre-filled syringe should be removed from the refrigerator and allowed to reach room temperature for approximately 30 minutes. The solution must be visually inspected to be clear and colorless; it must never be shaken. If prepared for IV infusion, the solution must be diluted only in 5% glucose solution.
Special Conditions	SC injection sites must be varied daily (e.g., abdomen, thigh) to prevent site soreness. In Severe Chronic Neutropenia, doses are individually adjusted every one to two weeks to maintain the Absolute Neutrophil Count (ANC) within a specific target range.

Connection to the Overall Use Protocol:

These instructions establish the precise method, timing, and dosage necessary for the drug's use. Following these guidelines, including the critical 24-hour time gap relative to chemotherapy and specific preparation steps, ensures the administration conforms strictly to prescribed standards.

Research Evidence / Overview of Studies for Tevagrastim

This section provides an overview of the clinical research and evidence base for Tevagrastim (Filgrastim), focusing on the types of studies conducted, the specific outcomes researchers monitored, and areas where data is still emerging.

---

Evidence for Use in Chemotherapy Support

This area of research is based on randomized controlled trials (RCTs) that have explored the use of Tevagrastim during the immediate period following intensive anti-cancer chemotherapy. The studies focused on short-term outcomes related to systemic or functional imbalance in populations with neutropenia.

The core evidence comes from pivotal biosimilarity studies, including a large trial involving patients with certain malignancies. Researchers examined whether Tevagrastim measured comparably to the reference medicine by focusing on the duration of severe neutropenia (DSN) and the incidence of febrile neutropenia (FN). These findings described patterns observed in the studies that were reported as comparable between Tevagrastim and the reference product.

Evidence in Stem Cell Collection and Transplantation Support

Research has also studied the use of the medicine to mobilize progenitor (stem) cells for collection. Researchers primarily measured the yield of CD34+ cells collected from the blood and the leukapheresis yield. The research evaluated the measured yield of CD34+ stem cells collected in studies comparing Tevagrastim and the reference product. After the transplantation procedure, studies monitored the interval required for patients to reach a target neutrophil count.

Evidence for Severe Chronic Neutropenia (SCN) Management

Research exploring the use of Tevagrastim in severe chronic neutropenia (SCN) involves conditions characterized by fluctuating manifestations and often relies on long-term observational studies. The studies examined the sustained measurement of the Absolute Neutrophil Count (ANC) above certain levels and monitored measurements of infection frequency and duration.

What is Still Uncertain About the Research Evidence

Key limitations noted in the research include: Long-term effects are not fully established for all indications; research on Overall Survival for chemotherapy support provided no consistent measurement; and data concerning the safety profile of the very high daily doses sometimes used in chronic conditions remain limited.

Key Studies & References Final Appraisal Report Filgrastim (TevaGrastim®) Teva UK Limited Advice No: 1410 – August 2010 (AWMSG Recommendation)

How to Store and Dispose of Tevagrastim?

Tevagrastim (Filgrastim) must be stored and disposed of according to official regulatory labeling to ensure product stability and safety.

Storage Requirements

The product must be stored continuously in a refrigerator at a temperature between 2°C and 8°C. It is critical not to freeze the medicine; if it becomes frozen, it must be discarded immediately. To protect the solution from light, the pre-filled syringe must be kept in the original outer carton.

If the medicine is removed from refrigeration, it can be kept at room temperature (not above 25°C) for a maximum single period of 24 hours, after which it must be discarded. The product must also be stored out of the sight and reach of children.

Disposal Instructions

Tevagrastim is for single use only, and any remaining solution must be discarded immediately after use. Unused medicine and waste material must be disposed of in accordance with local requirements and should not be placed in household waste or wastewater. Used syringes and needles must be placed into an approved puncture-resistant container.